The corporate liquidation process for genetic testing firm Invitae is nearing its formal conclusion. This stage represents the administrative endgame for investors, marking the terminal point of a prolonged restructuring effort. The company’s core diagnostic operations were fully transferred to a larger laboratory conglomerate two years ago, in 2024, leaving only the corporate shell to be wound down.
Administrators are now focused on finalizing the remaining legal and financial procedures. The pivotal event was the court-supervised transfer of the diagnostics division in 2024. Since that time, management has been resolving outstanding obligations. According to the established liquidation plan, equity shares are set to be largely…